US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Artiva Biotherapeutics, Inc.

3.74

-0.2900-7.20%

Post-market: 3.70-0.0400-1.07%17:33 EST

Volume:144.42K

Turnover:543.59K

Market Cap:91.80M

PE:-1.15

High:4.03

Open:4.03

Low:3.62

Close:4.03

52wk High:7.36

52wk Low:1.47

Shares:24.54M

Float Shares:5.38M

Volume Ratio:0.89

T/O Rate:2.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2458

EPS(LYR):-5.8064

ROE:-47.96%

ROA:-28.76%

PB:0.71

PE(LYR):-0.64

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)

Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data

Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares

US Stocks Mixed; NY Manufacturing Activity Dips In December

Artiva Biotherapeutics Replaces Underwater Stock Options with RSUs for Key Executives

Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares

Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development

Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases

Artiva Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge

Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results

BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners

BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global

Artiva Biotherapeutics Reports Positive AlloNK Trial Results

Artiva Biotherapeutics announces safety, translational data from AlloNK

Artiva Biotherapeutics Announces Positive Initial Data for AlloNK Cell Therapy in Autoimmune Disease Trials

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion With Allonk® in Autoimmune Disease

THOMSON REUTERS

Artiva Biotherapeutics Q3 EPS $(0.88), Inline

Artiva Biotherapeutics reports Q3 2025 results with $123 million cash and investments

Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARTV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARTV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":3.74,"timestamp":1770670800000,"preClose":4.03,"halted":0,"volume":144417,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.74,"latestTime":"17:33 EST","volume":233,"amount":868.9800240000001,"timestamp":1770676412091,"change":-0.04,"changeRate":-0.010695,"amplitude":0.010695},"delay":0,"changeRate":-0.07196029776674938,"floatShares":5381708,"shares":24544904,"eps":-3.245753,"marketStatus":"Post-Mkt","change":-0.29,"latestTime":"02-09 18:42:27 EST","open":4.03,"high":4.03,"low":3.62,"amount":543592.1156484,"amplitude":0.101737,"askPrice":4.5,"askSize":10,"bidPrice":3.7,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-3.245753,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":4.03,"preHourTrading":{"tag":"盘前","latestPrice":3.99,"preClose":4.03,"latestTime":"08:45 EST","volume":19,"amount":75.1700002,"timestamp":1770644726958,"change":-0.04,"changeRate":-0.009926,"amplitude":0.039702},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.74,"latestTime":"17:33 EST","volume":233,"amount":868.9800240000001,"timestamp":1770676412091,"change":-0.04,"changeRate":-0.010695,"amplitude":0.010695},"volumeRatio":0.885668},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","floatShares":5381708,"roa":"-28.76%","roe":"-47.96%","lyrEps":-5.806365,"volumeRatio":0.885668,"shares":24544904,"dividePrice":0,"high":4.03,"amplitude":0.101737,"preClose":4.03,"low":3.62,"week52Low":1.47,"pbRate":"0.71","week52High":7.36,"institutionHeld":0,"latestPrice":3.74,"committee":0.354839,"eps":-3.245753,"divideRate":0,"volume":144417,"delay":0,"ttmEps":-3.245753,"open":4.03,"prevYearClose":4.29,"prevWeekClose":4.03,"prevMonthClose":3.89,"prevQuarterClose":4.29,"fiveDayClose":4.18,"twentyDayClose":4.855,"sixtyDayClose":3.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARTV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ARTV","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.88},{"market":"US","date":"2025-08-06","symbol":"ARTV","fiscalQuarterEnding":"2025/06","expectedEps":-0.84,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.87},{"market":"US","date":"2025-05-08","symbol":"ARTV","fiscalQuarterEnding":"2025/03","expectedEps":-0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.83}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARTV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARTV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1735621200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARTV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARTV","date":"2026-02-06","current":-1.165061,"percent":0.566138,"low":-11.820615,"twenty":-5.015947,"median":-1.373111,"eighty":-0.880542,"high":-0.499349,"avg":-3.077672,"sd":3.296196,"marketCap":94988778},"quantilePoints":[{"date":"2024-08-02","current":-10.391793,"twenty":-10.391793,"median":-10.391793,"eighty":-10.391793,"marketCap":269833291},{"date":"2024-08-09","current":-9.862789,"twenty":-10.391793,"median":-10.042112,"eighty":-9.943484,"marketCap":256097171},{"date":"2024-08-16","current":-10.185571,"twenty":-10.248334,"median":-10.131774,"eighty":-9.95245,"marketCap":264478532},{"date":"2024-08-23","current":-8.939273,"twenty":-10.248334,"median":-10.051078,"eighty":-9.342751,"marketCap":232117163},{"date":"2024-08-30","current":-8.088598,"twenty":-10.185571,"median":-9.943484,"eighty":-9.046867,"marketCap":263081639},{"date":"2024-09-06","current":-8.893463,"twenty":-10.142533,"median":-9.800025,"eighty":-8.930111,"marketCap":289259885},{"date":"2024-09-13","current":-8.019798,"twenty":-10.131774,"median":-9.459311,"eighty":-8.763533,"marketCap":260843926},{"date":"2024-09-20","current":-8.759053,"twenty":-10.07439,"median":-9.028935,"eighty":-8.450238,"marketCap":284888199},{"date":"2024-09-27","current":-9.946342,"twenty":-10.07439,"median":-9.323455,"eighty":-8.581333,"marketCap":323504758},{"date":"2024-10-04","current":-11.499524,"twenty":-10.277026,"median":-9.57298,"eighty":-8.727691,"marketCap":374022017},{"date":"2024-10-11","current":-10.566121,"twenty":-10.505561,"median":-9.728296,"eighty":-8.794895,"marketCap":343663087},{"date":"2024-10-18","current":-9.543111,"twenty":-10.587029,"median":-9.800025,"eighty":-8.869568,"marketCap":310389700},{"date":"2024-10-25","current":-7.586699,"twenty":-10.505561,"median":-9.574426,"eighty":-8.581333,"marketCap":246757383},{"date":"2024-10-31","current":-7.579232,"twenty":-10.485041,"median":-9.464706,"eighty":-8.226879,"marketCap":246514511},{"date":"2024-11-08","current":-10.424244,"twenty":-10.485041,"median":-9.3863,"eighty":-8.226879,"marketCap":339048530},{"date":"2024-11-15","current":-4.166082,"twenty":-10.46953,"median":-9.378833,"eighty":-8.149728,"marketCap":255280837},{"date":"2024-11-22","current":-4.310765,"twenty":-10.439178,"median":-9.30416,"eighty":-7.969021,"marketCap":264146442},{"date":"2024-11-29","current":-5.065892,"twenty":-10.411264,"median":-9.046867,"eighty":-7.81669,"marketCap":310417611},{"date":"2024-12-06","current":-4.598149,"twenty":-10.334409,"median":-8.970887,"eighty":-7.365669,"marketCap":281756204},{"date":"2024-12-13","current":-4.233469,"twenty":-10.223229,"median":-8.939273,"eighty":-5.058757,"marketCap":259410023},{"date":"2024-12-20","current":-3.963922,"twenty":-10.173512,"median":-8.885996,"eighty":-4.852633,"marketCap":242893280},{"date":"2024-12-27","current":-4.17401,"twenty":-10.150694,"median":-8.781454,"eighty":-4.667914,"marketCap":255766623},{"date":"2025-01-03","current":-3.95203,"twenty":-10.131774,"median":-8.549971,"eighty":-4.598149,"marketCap":242164600},{"date":"2025-01-10","current":-4.066984,"twenty":-10.131774,"median":-8.396892,"eighty":-4.398368,"marketCap":249208505},{"date":"2025-01-17","current":-2.687539,"twenty":-10.07439,"median":-8.17661,"eighty":-4.337719,"marketCap":164681643},{"date":"2025-01-24","current":-2.477451,"twenty":-10.049285,"median":-8.109405,"eighty":-4.224748,"marketCap":151808300},{"date":"2025-01-31","current":-2.140518,"twenty":-10.011532,"median":-8.012331,"eighty":-4.193829,"marketCap":131162371},{"date":"2025-02-07","current":-1.823404,"twenty":-9.967928,"median":-7.881014,"eighty":-4.108209,"marketCap":111730908},{"date":"2025-02-14","current":-1.589533,"twenty":-9.948785,"median":-7.698708,"eighty":-3.978192,"marketCap":97400205},{"date":"2025-02-21","current":-1.502326,"twenty":-9.945199,"median":-7.508293,"eighty":-3.804572,"marketCap":92056553},{"date":"2025-02-28","current":-1.478543,"twenty":-9.911206,"median":-5.18038,"eighty":-2.77871,"marketCap":90599193},{"date":"2025-03-07","current":-2.0216,"twenty":-9.837683,"median":-5.059946,"eighty":-2.521847,"marketCap":123875572},{"date":"2025-03-14","current":-2.219796,"twenty":-9.795827,"median":-4.998506,"eighty":-2.343471,"marketCap":136020236},{"date":"2025-03-21","current":-1.601424,"twenty":-9.736345,"median":-4.76067,"eighty":-2.165887,"marketCap":98128885},{"date":"2025-03-28","current":-1.319282,"twenty":-9.624289,"median":-4.665536,"eighty":-2.054897,"marketCap":86245441},{"date":"2025-04-04","current":-0.946604,"twenty":-9.574715,"median":-4.606077,"eighty":-1.965312,"marketCap":61882322},{"date":"2025-04-11","current":-0.685729,"twenty":-9.561032,"median":-4.439593,"eighty":-1.797242,"marketCap":44828138},{"date":"2025-04-17","current":-0.857161,"twenty":-9.511749,"median":-4.37617,"eighty":-1.744126,"marketCap":56035173},{"date":"2025-04-25","current":-0.913063,"twenty":-9.383313,"median":-4.344458,"eighty":-1.606181,"marketCap":59689641},{"date":"2025-05-02","current":-0.883248,"twenty":-9.365642,"median":-4.233469,"eighty":-1.560992,"marketCap":57740592},{"date":"2025-05-09","current":-0.740531,"twenty":-9.335033,"median":-4.213649,"eighty":-1.495984,"marketCap":53111599},{"date":"2025-05-16","current":-0.723546,"twenty":-9.26085,"median":-4.193829,"eighty":-1.480232,"marketCap":51893443},{"date":"2025-05-23","current":-0.672592,"twenty":-9.079462,"median":-4.170046,"eighty":-1.376675,"marketCap":48238975},{"date":"2025-05-30","current":-0.696371,"twenty":-9.046867,"median":-4.104641,"eighty":-1.177664,"marketCap":49944393},{"date":"2025-06-06","current":-0.665798,"twenty":-9.028935,"median":-3.995633,"eighty":-0.946604,"marketCap":47751713},{"date":"2025-06-13","current":-0.696371,"twenty":-8.975602,"median":-3.957976,"eighty":-0.913063,"marketCap":49944393},{"date":"2025-06-20","current":-0.570684,"twenty":-8.968058,"median":-3.829149,"eighty":-0.909336,"marketCap":40930039},{"date":"2025-06-27","current":-0.533318,"twenty":-8.961769,"median":-2.822312,"eighty":-0.881757,"marketCap":38250096},{"date":"2025-07-03","current":-0.546906,"twenty":-8.947831,"median":-2.762854,"eighty":-0.830328,"marketCap":39224621},{"date":"2025-07-11","current":-0.60805,"twenty":-8.911787,"median":-2.592405,"eighty":-0.73948,"marketCap":43609983},{"date":"2025-07-18","current":-0.879805,"twenty":-8.888983,"median":-2.477451,"eighty":-0.736237,"marketCap":63100478},{"date":"2025-07-25","current":-1.168544,"twenty":-8.885996,"median":-2.34466,"eighty":-0.73948,"marketCap":83809129},{"date":"2025-08-01","current":-1.019079,"twenty":-8.836712,"median":-2.219796,"eighty":-0.740531,"marketCap":73089357},{"date":"2025-08-08","current":-0.856075,"twenty":-8.776974,"median":-2.136554,"eighty":-0.74119,"marketCap":64318634},{"date":"2025-08-15","current":-0.877783,"twenty":-8.664966,"median":-2.104843,"eighty":-0.766227,"marketCap":65949557},{"date":"2025-08-22","current":-0.90054,"twenty":-8.539516,"median":-2.017636,"eighty":-0.794855,"marketCap":67659360},{"date":"2025-08-29","current":-1.027331,"twenty":-8.461857,"median":-1.938358,"eighty":-0.806285,"marketCap":77185407},{"date":"2025-09-05","current":-1.011075,"twenty":-8.405106,"median":-1.906646,"eighty":-0.809828,"marketCap":75964119},{"date":"2025-09-12","current":-0.864778,"twenty":-8.31765,"median":-1.769891,"eighty":-0.816568,"marketCap":64972526},{"date":"2025-09-19","current":-0.773749,"twenty":-8.226879,"median":-1.740162,"eighty":-0.790778,"marketCap":58133313},{"date":"2025-09-26","current":-0.978565,"twenty":-8.17661,"median":-1.635118,"eighty":-0.805192,"marketCap":73521543},{"date":"2025-10-03","current":-0.959059,"twenty":-8.149728,"median":-1.601424,"eighty":-0.809828,"marketCap":72055997},{"date":"2025-10-10","current":-0.975314,"twenty":-8.101082,"median":-1.571695,"eighty":-0.816568,"marketCap":73277286},{"date":"2025-10-17","current":-0.90054,"twenty":-8.061078,"median":-1.530074,"eighty":-0.825779,"marketCap":67659360},{"date":"2025-10-24","current":-1.573506,"twenty":-8.013824,"median":-1.539983,"eighty":-0.830317,"marketCap":118220688},{"date":"2025-10-31","current":-1.280912,"twenty":-7.969021,"median":-1.537745,"eighty":-0.833281,"marketCap":96237502},{"date":"2025-11-07","current":-1.11836,"twenty":-7.90156,"median":-1.498363,"eighty":-0.837688,"marketCap":84024621},{"date":"2025-11-14","current":-1.102105,"twenty":-7.858868,"median":-1.490435,"eighty":-0.847643,"marketCap":82803333},{"date":"2025-11-21","current":-0.982565,"twenty":-7.819676,"median":-1.476561,"eighty":-0.856509,"marketCap":77807345},{"date":"2025-11-28","current":-1.16544,"twenty":-7.765913,"median":-1.457948,"eighty":-0.858684,"marketCap":92288839},{"date":"2025-12-05","current":-1.170089,"twenty":-7.585206,"median":-1.427209,"eighty":-0.865066,"marketCap":92657012},{"date":"2025-12-12","current":-0.973266,"twenty":-7.550856,"median":-1.356118,"eighty":-0.866579,"marketCap":77070998},{"date":"2025-12-19","current":-1.441302,"twenty":-7.413459,"median":-1.35655,"eighty":-0.869582,"marketCap":114133803},{"date":"2025-12-26","current":-1.332817,"twenty":-7.317879,"median":-1.35655,"eighty":-0.875795,"marketCap":105543087},{"date":"2026-01-02","current":-1.329717,"twenty":-5.60788,"median":-1.355686,"eighty":-0.876285,"marketCap":105297638},{"date":"2026-01-09","current":-1.419605,"twenty":-5.08879,"median":-1.356118,"eighty":-0.877508,"marketCap":112415660},{"date":"2026-01-16","current":-1.38241,"twenty":-5.065892,"median":-1.373111,"eighty":-0.877783,"marketCap":109470271},{"date":"2026-01-23","current":-1.534289,"twenty":-5.058757,"median":-1.38241,"eighty":-0.877783,"marketCap":121497274},{"date":"2026-01-30","current":-1.286323,"twenty":-5.046865,"median":-1.38396,"eighty":-0.878996,"marketCap":101861351},{"date":"2026-02-06","current":-1.199535,"twenty":-5.015947,"median":-1.373111,"eighty":-0.880542,"marketCap":94988778}],"updateTime":1770654759612},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARTV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605481145","title":"Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481145?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:40","pubTimestamp":1769013615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Artiva ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","TRVI","BK4137","BK4581","ARTV","BK4007","LU0029874061.USD","ONCY","BK4585","XLV","XBI","LABU","HCSG","BK4588","BK4139"],"gpt_icon":0},{"id":"2605021271","title":"Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2605021271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605021271?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000434,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. announced upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The company will present new data on the cost-effectiveness of its off-the-shelf NK cell therapy, AB-101 , in outpatient community rheumatology practices, highlighting its comparison to CAR-T treatments for rheumatologic diseases. Additionally, updated results on the continued durability of AlloNK in patients with relapsed or refractory Non-Hodgkin Lymphoma will be shared. These results will be presented as poster sessions during the conference and have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLbQJJGk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","ARTV","BK4112","NDAQ","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2591719356","title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591719356","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591719356?lang=en_us&edition=fundamental","pubTime":"2025-12-16 10:20","pubTimestamp":1765851602,"startTime":"0","endTime":"0","summary":"Fred Aslan, President and CEO of Artiva Biotherapeutics Inc., reported a disposal of common shares of Artiva Biotherapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLb5JZFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2591647230","title":"US Stocks Mixed; NY Manufacturing Activity Dips In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647230","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647230?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:02","pubTimestamp":1765810978,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49394249/us-stocks-mixed-ny-manufacturing-activity-dips-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRBTQ","MASK","MNQmain",".IXIC","QLD","BK4139","BK4187","TQQQ","BK4191","IRBT","ARTV","USJW.SI","TSYW.SI","BK4209","USAW.SI","BK4585","NVIW.SI","BK4567","SQQQ","MNTS","BK4134","AMCI","PSQ","QID","BK4547","BK4604","NQmain"],"gpt_icon":1},{"id":"2591684221","title":"Artiva Biotherapeutics Replaces Underwater Stock Options with RSUs for Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684221?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:24","pubTimestamp":1765578272,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. has implemented a new equity compensation arrangement for select employees, including President and CEO Fred Aslan and COO Jennifer Bush. Under Option for RSU Exchange Agreements, eligible participants were given a one-time opportunity to exchange outstanding stock options with exercise prices above the current market value for restricted stock units  granted under the 2024 Equity Incentive Plan. As part of the exchange, Dr. Aslan surrendered options for 869,136 shares and received an equivalent number of RSUs, while Ms. Bush exchanged options for 84,877 shares for RSUs. The RSUs granted in exchange for vested options will vest in installments between August 2026 and February 2027, with full acceleration possible upon certain termination events. RSUs granted for unvested options will vest between August 2026 and February 2029, with partial acceleration in specific circumstances. The RSU grants became effective on December 12, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL69fXnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2584860926","title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584860926","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584860926?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:38","pubTimestamp":1763429907,"startTime":"0","endTime":"0","summary":"Fred Aslan, President and CEO of Artiva Biotherapeutics Inc., reported a disposal of common shares of Artiva Biotherapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4DHCKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2583532521","title":"Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583532521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583532521?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:42","pubTimestamp":1763008921,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q3 earnings. Here is a breakdown of the information Artiva Biotherapeutics, Inc. presente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-increased-losses-amid-ongoing-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-increased-losses-amid-ongoing-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2583258591","title":"Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258591?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:35","pubTimestamp":1762983351,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating today. Tyler Van Buren has given his Buy ra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-artiva-biotherapeutics-allonk-therapy-for-autoimmune-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-artiva-biotherapeutics-allonk-therapy-for-autoimmune-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2583644304","title":"Artiva Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583644304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583644304?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:03","pubTimestamp":1762974180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 14:03 ET (19:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2583301404","title":"Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2583301404","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583301404?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:25","pubTimestamp":1762971924,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham reiterated a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $18.00. Gil Blum ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-artiva-biotherapeutics-inc-based-on-promising-clinical-results-and-competitive-edge-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-artiva-biotherapeutics-inc-based-on-promising-clinical-results-and-competitive-edge-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2583306727","title":"Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583306727","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583306727?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:05","pubTimestamp":1762967129,"startTime":"0","endTime":"0","summary":"Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Artiva Biotherapeutics, Inc.. The associated price target was raised to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-artiva-biotherapeutics-based-on-promising-allonk-combination-therapy-results-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-artiva-biotherapeutics-based-on-promising-allonk-combination-therapy-results-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2582303647","title":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2582303647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582303647?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:56","pubTimestamp":1762962963,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCO","LU2471134523.USD","LU0823421416.USD","BK4179","LU0882574055.USD","MBRX","BHVN","VVX","LU0096364046.USD","XOM","LU0278409577.USD","LU2552382132.HKD","BBWI","FND","BROS","LWAY","FTCI","CVX","BKR","LB","SBUX","BHF","CRMD","LEGN","ARTV","VG","PBF","LU0795875086.SGD","LU2471134879.HKD","NEM","LU1223082196.USD","VLN","T","ALKS","AMD","KGS","IBM","LCID","LU0823421333.USD","FLNG","COGT","YTRA","CWAN","LU0208291251.USD","LU0788109394.HKD","CRWS","CREX"],"gpt_icon":1},{"id":"2582727653","title":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2582727653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582727653?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:13","pubTimestamp":1762956792,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCID","LU2458330243.SGD","LU0096364046.USD","VLN","CWAN","LU2471134879.HKD","BBWI","VG","LU0456854461.SGD","LU2750360641.GBP","LU1883866441.USD","BHVN","CREX","CRWS","LU0788109394.HKD","LU0109392836.USD","ARTV","LU2471134523.USD","LU0795875086.SGD","LU0278409577.USD","LU0823434583.USD","SG9999015945.SGD","LU0109394709.USD","CRMD","MBRX","FLNG","LU2471134796.USD","LU0354030511.USD","FTCI","YTRA","VVX","LU0943347566.SGD","LU2750360997.AUD","LU0823421416.USD","XOM","LU0882574055.USD","IBM","LU0823434740.USD","LU0300736492.USD","LU0321505868.SGD","KGS","COGT","ARCO","LU0823421333.USD","LU2552382132.HKD","LU2458330169.SGD","ALKS"],"gpt_icon":1},{"id":"2582379647","title":"Artiva Biotherapeutics Reports Positive AlloNK Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379647","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379647?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:52","pubTimestamp":1762951975,"startTime":"0","endTime":"0","summary":"An update from Artiva Biotherapeutics, Inc. ( ($ARTV) ) is now available. On November 12, 2025, Artiva Biotherapeutics announced positive initial s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-positive-allonk-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/artiva-biotherapeutics-reports-positive-allonk-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2582376105","title":"Artiva Biotherapeutics announces safety, translational data from AlloNK","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376105","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376105?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762951000,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (ARTV) announced positive initial safety and translational data from ongoing clinical trials of AlloNK in combination with r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-announces-safety-translational-data-from-allonk-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-announces-safety-translational-data-from-allonk-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2582375236","title":"Artiva Biotherapeutics Announces Positive Initial Data for AlloNK Cell Therapy in Autoimmune Disease Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375236","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375236?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:20","pubTimestamp":1762950012,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. announced positive initial safety and translational data from ongoing clinical trials of AlloNK , an allogeneic, off-the-shelf natural killer  cell therapy, in combination with rituximab or obinutuzumab for the treatment of autoimmune diseases. The results, which were presented during a company webcast, indicate that AlloNK was generally well tolerated and demonstrated deep B-cell depletion in outpatient and community settings. Artiva remains on track to share initial clinical response data and conduct regulatory interactions with the U.S. Food and Drug Administration  to align on the pivotal trial design for AlloNK in refractory rheumatoid arthritis  in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLdCM8Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","ARTV","NDAQ","LU2210149790.SGD","LU2210150020.SGD","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582754883","title":"Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion With Allonk® in Autoimmune Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2582754883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582754883?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:20","pubTimestamp":1762950000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUAB0QFBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2582375545","title":"Artiva Biotherapeutics Q3 EPS $(0.88), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375545","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375545?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:13","pubTimestamp":1762949618,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Q3 EPS $(0.88), Inline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799228/artiva-biotherapeutics-q3-eps-0-88-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2582732843","title":"Artiva Biotherapeutics reports Q3 2025 results with $123 million cash and investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2582732843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582732843?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948868,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc. reported cash, cash equivalents, and investments of $123.0 million as of September 30, 2025, expected to fund operations into the second quarter of 2027. Research and development expenses were $17.6 million for the three months ended September 30, 2025, up from $13.5 million for the same period in 2024. General and administrative expenses totaled $5.3 million, compared to $4.8 million for the prior year period. Other income, net, was $1.4 million, compared to $0.9 million for the same period in 2024. During the quarter, Artiva announced a CFO transition and highlighted ongoing clinical trials, with initial clinical response data in refractory rheumatoid arthritis expected in the first half of 2026 and plans for FDA discussions regarding potential pivotal trial design.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8Qf3wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","BK4585","ARTV","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2582734693","title":"Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582734693","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582734693?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"Over 100 patients treated with AlloNK across autoimmune and oncology indications. Refractory rheumatoid arthritis  prioritized as lead indication following FDA Fast Track Designation for AlloNK, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA. Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across autoimmune diseases; presentation to also include outpatient feasibility and tolerability observations. Initial clinical response data in refractory RA expected in the first half of 2026, with FDA discussions planned to align on potential pivotal trial design in refractory RA. Cash runway into Q2 2027, with cash, cash equivalents, and investments of $123.0 million as of September 30, 2025. SAN DIEGO, Nov. 12, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose missio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","RA","ARTV","R","BK4139","BK4232"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}